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Many factors, including disproportionate growth rates and exciting new technologies, have
focused attention on cardiovascular imaging. However, critical examination of the field reveals
a surprisingly weak evidence base and inconsistent systematic attention to quality improve-
ment. Remedies span research and practice. The optimal clinical continuum of care begins
with ensuring a proper match between the diagnostic test and the individual’s clinical
question, and progresses to include image acquisition, image interpretation, and results
reporting. Better research methodologies are needed to more tightly link imaging use to
improved outcomes in non-biased community populations. To accomplish these lofty goals,
alignment across stakeholders is needed to ensure the necessary human and capital investment
in research and systems of care. (J Am Coll Cardiol 2006;48:2152–5) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.107American College of Cardiology Foundation
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supply.
Donabedian (1)
Knowing is not enough; we must apply. Willing is not enough;
we must do.
Goethe (2)
ailed as one of the top 11 medical advances in the past
,000 years (3), imaging in general, and cardiovascular (CV)
maging in particular, has contributed significantly to the
triking reduction in cardiovascular mortality over the last
0 years. However, growth rates of as high as 26% per year,
ore than any other component of medical care, have also
aptured the attention of payers and regulators (4,5). The
ppeal of imaging is obvious—we all love a pretty picture—
nd extends to patients as well as physicians. However, in
his time of budgetary constraint, how can we be sure that
maging is providing value? When the rate of use of CV
maging varies as much as 3-fold to 4-fold in different
egions across the U.S., as it does for echocardiography (6),
ow can we be sure that such testing is being performed well
nd to our patients’ benefit?
Although most CV imaging is noninvasive, even such
eemingly innocuous tests may cause harm; a patient with
alse-positive test results may subsequently have an unnec-
ssary invasive procedure, or a patient with false-negative
est results may not receive life-saving treatment. The
vidence base supporting the clinical use or benefit of an
maging procedure is limited and problematic. Current
maging research is often performed in nonrandomized
opulations referred to academic centers, resulting in sig-
ificant referral bias, and the usual comparisons to gold
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Manuscript received March 28, 2006, accepted April 12, 2006.tandards are plagued by verification bias. We generally
valuate tests, and not diagnostic strategies, so that imaging
esearch is not patient oriented. There is a lack of consensus
n the definition of quality in imaging, with the result that
here are few quality standards. For example, of the 745
ecommendations on imaging in the American College of
ardiology/American Heart Association (ACC/AHA)
linical Guidelines, there is a striking disconnect between the
lass of the recommendations (51% are class 1) and the level of
vidence (only 1% are level 1, whereas 54% are level 3), which
upports these recommendations (Fig. 1). Finally, efforts to
mprove imaging quality are quite limited, especially in
omparison to the national performance measures used in
ther areas of cardiovascular medicine (7,8), which have
volved to encompass nationally agreed-on standards, which
n turn form the basis for hospital pay-for-performance
rograms and public reporting.
One reason for the lack of a robust evidence base in
maging is the federal approval process. Advances in imag-
ng require few regulatory approvals to implement so that
he requirements for U.S. Food and Drug Administration
10K approval are minimal compared with those needed to
ring a new medication to market. As a result, there is little
ncentive for the imaging industry to support or academic
nvestigators to perform extensive clinical research, much
ess the large randomized trials that form the basis for much
f today’s clinical CV care. Indeed, regulatory approval is
riven by technology, rather than by clinical utility, and the
urrent approval process too often fails to advance knowl-
dge in the field. This situation critically constrains efforts to
etermine the proper place of existing imaging or of new
echnologies such as computed tomography angiography in
he clinical armamentarium and in payers’ coverage policies.
lthough extensive reform of this process is unlikely, small
fforts, such as requiring a basic level of information technol-
gy interoperability for approval of new imaging equipment,
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November 21, 2006:2152–5 Improving Imagingould be both easier to implement and a welcome stimulus
oward much-needed reform.
At the core of the problem is the difficulty in connecting
erformance of an imaging test to a health-related outcome.
atients rarely live or die on the basis of performance of a
oninvasive test. Instead imaging outcomes (if assessed at
ll) are generally evaluated in a hierarchical fashion that
ncludes the intermediate, but hard to measure, steps of impact
n diagnostic and therapeutic thinking (9,10) (Table 1). In this
chema, the initial step in imaging outcomes is technical
apability, which generally includes engineering and equip-
ent specifications. This is followed by test performance,
hich includes conventional measures of sensitivity, speci-
city, negative and positive predictive values, and overall
ccuracy, usually determined in reference to a gold standard.
oth of these domains are commonly investigated as part of
he evaluation of a new imaging test; however, most
ssessments stop at this stage. Higher levels of imaging
utcomes include impact on diagnostic or prognostic think-
ng (e.g., the patient with a positive stress test result may
ow be diagnosed with coronary artery disease, and is
tratified into a high or low risk group for a future ischemic
vent). This is followed by impact on diagnostic or thera-
eutic strategies (e.g., the patient with newly diagnosed
oronary artery disease may or may not need additional
esting, lipid lowering and other preventive medications
hould be added or avoided, a therapeutic procedure is
ndicated or not, and so on). Finally, the highest level
nvolves financial, health-related, and patient and provider
atisfaction outcomes (e.g., as a result of testing, will this
atient live a longer and healthier life, was the performance
f this imaging test a cost-effective strategy for this patient,
as the patient’s experience optimal).
One of the cornerstones of evidence-based medicine is a
ontinuous cycle of improvement that links the introduction
f new therapies to an evaluation process and to patient
utcomes, which in turn informs further therapeutic devel-
pment. There is no analogous cycle in imaging. Instead,
he current “cycle” of imaging begins at technology devel-
pment, moves to evaluation of technical capability (e.g.,
est performance characteristics), and then rapidly moves to
eimbursement and clinical use (Fig. 2A). Instead, a true
ycle would consist of technology development informing
echnical capability, which in turn would drive the assess-
ent of diagnostic utility and therapeutic strategy, and only
hen move on to reimbursement. Once a test is reimbursed,
urther investigation is needed to track implementation and
Abbreviations and Acronyms
ACC/AHA  American College of Cardiology/
American Heart Association
CV  cardiovascularo develop guidelines and appropriateness criteria, which in
r
curn impact patient outcomes and finally influence the next
eneration of technology development (Fig. 2B).
Clearly there is a need for substantial improvement in
maging research, including the development and adoption
f a viable, evidence-based imaging cycle. Because research-
rs have not yet developed the appropriate analytic meth-
dologies to properly evaluate imaging outcomes, we need
o focus on developing pragmatic research methods. One
uch method has been proposed for the implementation of
ew technology that uses time-varying physician confidence
nd test referral patterns as independent judges of the new
est’s value (11). Academic centers should target the develop-
ent of imaging evaluation centers that include outcomes and
uality evaluation as well as analysis of test performance.
imilarly, we need to develop and implement standards for
sing imaging in clinical trials (12). Imaging registries
ould also be highly desirable, particularly across modali-
ies, and would require definition of key data elements and
niform structured reporting with concordance among dif-
erent tests. Local ad hoc registries, unconnected to national
ata repositories, are already being developed as payers
equire participation as a condition of reimbursement for
ewer tests, such as computed tomography angiography.
maging quality needs to be better defined, the methods to
chieve it agreed on and implemented, and the impact on
igure 1. (A) Current American College of Cardiology/American Heart
ssociation (ACC/AHA) Guidelines contain a total of 745 recommenda-
ions on the use of imaging, with just over one-half being class I, indicating
hat the procedure is beneficial, useful, and effective, and only 18% class II,
ndicating that the procedure is not useful or effective and may be harmful.
B) The level of evidence to support the use of imaging used in the
CC/AHA Guidelines is in contrast to the class of the recommendations.
he majority are level 3, indicating that the recommendation is supported
nly by the consensus opinion of experts, case studies, or standard-of-care,
ather than representing level 1 evidence derived from multiple randomized
linical trials.
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Improving Imaging November 21, 2006:2152–5utcomes measured. In general, all of these efforts will help
o enable improvement in imaging effectiveness and efficacy
s well as efficiency in clinical practice.
Quality efforts in CV imaging need to focus on critical
omponents of imaging care. Beginning with the patient,
he first step is ensuring an optimal match between the
iagnostic test and the individual’s clinical question. This is
redominantly the responsibility of the ordering physician
nd can be guided by the new ACC appropriateness criteria
eries of documents (13,14). After an appropriate match is
igure 2. (A) The current process of imaging development requires only d
ubsequent clinical adoption, without a need for demonstration of clinical
f such use and few guidelines directed at ensuring appropriate care. Fin
able 1. Measuring Imaging Outcomes: A Hierarchy of Value
Technical capability
Test performance, accuracy
Diagnostic/prognostic thinking
Diagnostic/therapeutic strategies
Outcomes, cost effectiveness
Patient satisfaction
ata from Guyatt et al. (9) and Fryback et al. (10).echnology development. (B) An ideal cycle of imaging development would in
ncorporation into clinical care as well as the development of new imaging technsured, images that are complete and interpretable need to
e acquired by a skilled technologist, with minimal harm to
he patient. (Harm may come in the form of radiation or
ontrast agent use for some imaging tests.) Images need to
e interpreted by a skilled physician, with quality controls
nd processes in place to minimize intraobserver and inter-
bserver variability and to maximize comparability with
tandard image sets. Results need to be communicated in a
imely, clinically relevant, and definitive manner to the
eferring physician so that they can be incorporated into
linical care planning and thereby impact patient outcomes.
eports should be complete and electronically accessible,
ith standardized data elements and cross-correlation
cross all imaging modalities. Current laboratory accredita-
ion processes address some but by no means all of these
ssues. In addition, they represent a single “snapshot” of
uality, often at 3-year intervals, rather than providing a
echanism for ongoing assessment and improvement.
stration of technical capability or test performance for reimbursement and
y. Further, there are few intermediate steps designed to assess the impact
it is linear, with little feedback from clinical experience onto subsequentemon
utilit
ally,corporate all of these steps into a continuous creation of evidence and
nology.
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November 21, 2006:2152–5 Improving ImagingAlthough the need for change is apparent, there are also
any barriers. We need to aim high with a concrete plan for
eform, and coordinate our efforts. Research and data
ollection are critical to support the value of quality im-
rovement programs in imaging and to provide momentum
nd justification for ongoing efforts. Hospitals, payers, and
roviders need to agree on uniform sets of metrics and to
lign their efforts accordingly. Improved information tech-
ology is an essential platform for communication between
eferring and interpreting providers with facilitation of a
-way flow of vital information in a user-friendly, distrib-
ted, and timely way. Enhanced information technology is
lso necessary to implement ongoing monitoring and im-
rovement of quality. Because there is as yet little regulatory
r financial pressure for the required system redesign,
ommitted leadership is critical, as is alignment of financing
nd funds flow to support quality and research efforts. We
eed to minimize the regulatory processes so that the
urden of compliance is minimized. Physicians and hospi-
als need to discard the fears of litigation that often
ccompany contemplation of admitting to providing less
han optimal care.
The path is clear. Creation of a robust body of clinical
vidence regarding the value of imaging is long overdue. It
s a necessary foundation for any quality improvement
rocess, which can no longer be based on the educated
uesses that inform our current consensus model. Without
n explicit evidence base it will be impossible to build the
uidelines, appropriateness criteria, and other performance
easures that will form the core of quality programs that in
urn are needed to drive improvement of real-world results.
artnerships of providers, hospitals, government, profes-
ional societies, payers, and industry are critical. All stake-
olders need to recognize that imaging and imaging quality
annot be taken for granted any longer. They deserve the
ame attention to research and outcomes, enhancement of
erformance, and care delivery as other interventions. These
re inescapable components of ensuring imaging’s proper
lace in the clinical arena.eprint requests and correspondence: Dr. Pamela S. Douglas,
uke University Medical Center 3943, Duke North 7451, Durham,
orth Carolina 27710. E-mail: pamela.douglas@duke.edu.
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